Inflammatory pathways are linked to carcinogenesis and progression, and cancer patients often have elevated levels of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) and expansion of regulatory cells (myeloid-derived suppressor cells and Tregs) [331]. This evidence concerns the gene IL6 and cancer.